A systematic review of ketamine's anxiolytic potential in rodent behavioral models of anxiety and PTSD

IF 2.4 3区心理学 Q1 BEHAVIORAL SCIENCES

Pharmacology Biochemistry and Behavior Pub Date : 2026-02-01 Epub Date: 2025-12-12 DOI:10.1016/j.pbb.2025.174144

Alena Lemeshova , Kaya A. Patel , Alexander J. Bloom, Lindsay Golan, Haney Haidari, Aiman Limbada, Cherish Zhao, Jennifer A. Honeycutt

{"title":"A systematic review of ketamine's anxiolytic potential in rodent behavioral models of anxiety and PTSD","authors":"Alena Lemeshova , Kaya A. Patel , Alexander J. Bloom, Lindsay Golan, Haney Haidari, Aiman Limbada, Cherish Zhao, Jennifer A. Honeycutt","doi":"10.1016/j.pbb.2025.174144","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Ketamine, a nonselective NMDA-receptor antagonist, is an emerging therapeutic for treatment-resistant depression and could also be a promising treatment for anxiety and post-traumatic stress disorders. However, preclinical studies in these areas lack methodological standardization, limiting clinical translatability. This review evaluates ketamine's anxiolytic potential in rodents by examining outcomes among different animal models, dosages, and treatment timing.</div></div><div><h3>Methods & Results</h3><div>A PubMed search of studies published up to July 21, 2025, identified 562 articles assessing ketamine's effects on anxiety and PTSD in rodent models. After applying inclusion and exclusion criteria, 35 studies were analyzed. Key methodological variables, model type, dosage, and timing were summarized to assess consistency and effectiveness across studies.</div></div><div><h3>Conclusion</h3><div>Current research on ketamine's anxiolytic potential in rodents is limited by inconsistent methods and inadequate sex inclusion. Evidence suggests that administering 10 to 30 mg/kg intraperitoneally and waiting ≥24 h before behavioral testing procedures produces anxiolytic effects, in deficit models. Future studies should include female subjects and standardized designs to enhance clinical translatability and relevance.</div></div>","PeriodicalId":19893,"journal":{"name":"Pharmacology Biochemistry and Behavior","volume":"259 ","pages":"Article 174144"},"PeriodicalIF":2.4000,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacology Biochemistry and Behavior","FirstCategoryId":"102","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0091305725001911","RegionNum":3,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/12/12 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"BEHAVIORAL SCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Ketamine, a nonselective NMDA-receptor antagonist, is an emerging therapeutic for treatment-resistant depression and could also be a promising treatment for anxiety and post-traumatic stress disorders. However, preclinical studies in these areas lack methodological standardization, limiting clinical translatability. This review evaluates ketamine's anxiolytic potential in rodents by examining outcomes among different animal models, dosages, and treatment timing.

Methods & Results

A PubMed search of studies published up to July 21, 2025, identified 562 articles assessing ketamine's effects on anxiety and PTSD in rodent models. After applying inclusion and exclusion criteria, 35 studies were analyzed. Key methodological variables, model type, dosage, and timing were summarized to assess consistency and effectiveness across studies.

Conclusion

Current research on ketamine's anxiolytic potential in rodents is limited by inconsistent methods and inadequate sex inclusion. Evidence suggests that administering 10 to 30 mg/kg intraperitoneally and waiting ≥24 h before behavioral testing procedures produces anxiolytic effects, in deficit models. Future studies should include female subjects and standardized designs to enhance clinical translatability and relevance.

查看原文本刊更多论文

氯胺酮在啮齿动物焦虑和创伤后应激障碍行为模型中的抗焦虑潜力的系统综述。

背景：氯胺酮是一种非选择性nmda受体拮抗剂，是治疗难治性抑郁症的一种新兴疗法，也可能是治疗焦虑和创伤后应激障碍的一种有希望的治疗方法。然而，这些领域的临床前研究缺乏方法标准化，限制了临床可翻译性。本综述通过检查不同动物模型、剂量和治疗时间的结果来评估氯胺酮在啮齿动物中的抗焦虑潜能。方法和结果：PubMed检索了截至2025年7月21日发表的研究，确定了562篇评估氯胺酮对啮齿动物模型焦虑和创伤后应激障碍影响的文章。应用纳入和排除标准后，对35项研究进行分析。总结了关键的方法学变量、模型类型、剂量和时间，以评估研究的一致性和有效性。结论：氯胺酮对啮齿动物抗焦虑作用的研究存在方法不统一、性别不充分等问题。有证据表明，在缺陷模型中，腹腔注射10至30 mg/kg并等待≥24 h后进行行为测试可产生抗焦虑作用。未来的研究应包括女性受试者和标准化设计，以提高临床可翻译性和相关性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacology Biochemistry and Behavior 医学-行为科学

CiteScore

6.40

自引率

2.80%

发文量

122

审稿时长

38 days

期刊介绍： Pharmacology Biochemistry & Behavior publishes original reports in the areas of pharmacology and biochemistry in which the primary emphasis and theoretical context are behavioral. Contributions may involve clinical, preclinical, or basic research. Purely biochemical or toxicology studies will not be published. Papers describing the behavioral effects of novel drugs in models of psychiatric, neurological and cognitive disorders, and central pain must include a positive control unless the paper is on a disease where such a drug is not available yet. Papers focusing on physiological processes (e.g., peripheral pain mechanisms, body temperature regulation, seizure activity) are not accepted as we would like to retain the focus of Pharmacology Biochemistry & Behavior on behavior and its interaction with the biochemistry and neurochemistry of the central nervous system. Papers describing the effects of plant materials are generally not considered, unless the active ingredients are studied, the extraction method is well described, the doses tested are known, and clear and definite experimental evidence on the mechanism of action of the active ingredients is provided.